TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16076919
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly plus calcium carbonate 500 mg daily
Study: 16076919
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 500 mg daily
Study: 10407719
Drug: Surviving Cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surviving Cancer Competently Intervention Program (SCCIP) - a one-day family group intervention combining cognitive-behavioral and family therapy approaches
Study: 6767517
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 50 g of mannitol 2 hours before whole bowel irrigation (WBI)
Study: 28741061
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for 1 week followed by 3 weeks of placebo
Study: 27918731
Drug: Passiflora incarnata
Normalized name: Passiflora incarnata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora incarnata (260 mg)
Study: 25140866
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg guanfacine (n=50)
Study: 16419687
Drug: Sodium enoxaparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium enoxaparin, administered subcutaneously at a dose of 2,000 IU twice daily for 10 days
Study: 9443710
Drug: Peptide T
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide T (2 mg, intranasally, 3 times a day for 6 months)
Study: 7152082
Drug: Disophrol Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disophrol Syrup
Study: 7152082
Drug: Rinomar Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinomar Syrup
Study: 23652578
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ranibizumab monthly for 12 months
Study: 23652578
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ranibizumab monthly for 3 months and then pro re nata
Study: 23652578
Drug: high-dose 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose 2.0 mg of ranibizumab monthly for 12 months
Study: 23652578
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter
Study: 19389714
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg daptomycin administered as a 30 min iv infusion
Study: 19389714
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg daptomycin administered as a 2 min iv injection
Study: 19389714
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg daptomycin administered as a 2 min iv injection
Study: 15036854
Drug: Cs-137 low-dose-rate
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cs-137 low-dose-rate brachytherapy (60-75 Gy at 1.4-1.8 Gy/h)
Study: 15036854
Drug: Ra-226 low-dose-rate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ra-226 low-dose-rate brachytherapy (75 Gy at 0.5 Gy/h)
Study: 12205256
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroxine (T4) treatment
Study: 9220504
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl combined with midazolam
Study: 9220504
Drug: Intramuscular meperidine‐promethazine‐chlorpromazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine‐promethazine‐chlorpromazine (MPC) compound
Study: 2443087
Drug: 3% NaCl
Normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% NaCl (12 mL/kg)
Study: 2443087
Drug: 7.5% NaCl/dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% NaCl/dextran 70 (250 mL)
Study: 12362423
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 2 gm/kg at induction and 1 gm/kg after 3 weeks
Study: 12443959
Drug: Third-generation oral
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Third-generation oral contraceptives (specific dosage and duration not mentioned)
Study: 1781523
Drug: Clonidine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (two doses)
Study: 1781523
Drug: Saline (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (inert treatment)
Study: 7008894
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine
Study: 28560779
Drug: S‐(‐)‐amlodipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐(‐)‐amlodipine 2.5 mg/d (low dose)
Study: 28560779
Drug: S‐(‐)‐amlodipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐(‐)‐amlodipine 5 mg/d (high dose)
Study: 28560779
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between high and low dose groups
Study: 19182688
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus medication change
Study: 17440209
Drug: Goal-discrepant situations
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-discrepant situations (e.g., having dirty shoes)
Study: 9489597
Drug: L-arginine (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (17 mg kg[‐1] min[‐1], infusion period 30 min)
Study: 9489597
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (5.0 ng kg[‐1] min[‐1], infusion period 75 min)
Study: 8157352
Drug: Active multi-vitamin
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active multi-vitamin multi-mineral supplement
Study: 29982631
Drug: Golimumab maintenance
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab maintenance therapy
Study: 29982631
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to induction treatment
Study: 29982631
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to induction treatment
Study: 23500894
Drug: Internet-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based training (IBT) in cognitive behavioural therapy (CBT) theory, assessment and formulation (approximately three hours over the course of one month)
Study: 21687923
Drug: Vibrating plate
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vibrating plate via reciprocation therapy
Study: 3918683
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration fluid plus breast feeding
Study: 3918683
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration fluid alone
Study: 30247704
Drug: Pregnancy 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnancy 25(OH)D >125 nmol/L
Study: 15140776
Drug: budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide 9 mg daily
Study: 15140776
Drug: prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 7.5 mg daily
Study: 15140776
Drug: budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide 3 mg daily
Study: 10521759
Drug: Systemic methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic methotrexate administration
Study: 1660411
Drug: Retroperitoneal lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneal lymph node dissection (RPLND) prior to chemotherapy
Study: 1660411
Drug: Retroperitoneal lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneal lymph node dissection (RPLND) after initial chemotherapy
Study: 6131630
Drug: Fazadinium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium (1 mg . kg‐1)
Study: 6131630
Drug: Alcuronium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium (0.2 mg . kg‐1)
Study: 6131630
Drug: Pancuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.08 mg . kg‐1)
Study: 27571052
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of wild blueberries for 30 days
Study: 22067666
Drug: 3% StarPharma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% StarPharma LTD 7013 gel (VivaGel)
Study: 22067666
Drug: Placebo (carbopol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (carbopol gel without StarPharma LTD 7013)
Study: 16418138
Drug: Optimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal therapy (target: <120/80 mm Hg)
Study: 16418138
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (target: <140/90 mm Hg)
Study: 31587090
Drug: Personalised dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised dosing algorithm based on warfarin PK/PD model
Study: 31587090
Drug: Conventional weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional weight-based dosing
Study: 31587090
Drug: Model-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based dosing (Group 2)
Study: 31587090
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing (Group 2)
Study: 25643509
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg daily divided into 3 doses for 7 days
Study: 25643509
Drug: Lactulose syrup
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose syrup (laxolac) 90 ml daily divided into 3 doses for 7 days
Study: 17371829
Drug: DX-619 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-619 (800 mg, intravenous, once daily for 4 days)
Study: 17371829
Drug: Placebo (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous, once daily for 4 days)
Study: 16015059
Drug: Noninvasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive therapy
Study: 12566753
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg per day)
Study: 12566753
Drug: Flutamide plus
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide plus oral contraceptive (250 mg flutamide + 35 microg ethinyl estradiol + 2 mg cyproterone acetate per day)
Study: 12566753
Drug: Flutamide plus
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide plus oral contraceptive
Study: 819984
Drug: Taurine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (200 mg/Kg i.v. administration) for 15 consecutive days, then once a week for 6 weeks
Study: 819984
Drug: Taurine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (200 mg/Kg i.v. administration)
Study: 25458646
Drug: Bivalirudin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin infusion
Study: 31883294
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) infusion
Study: 25252593
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment (1W, 100mj, 1064nm)
Study: 23551409
Drug: Yangxue Qingnao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxue Qingnao Granules (YXQNG) 12 g/day
Study: 23551409
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg/day
Study: 21300177
Drug: KAN-DO intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAN-DO intervention (mailed family kits encouraging healthy lifestyle change, 8 monthly kits, motivational counseling calls, and a single group session)
Study: 15309209
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACE inhibitors)
Study: 15309209
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics (high doses)
Study: 15309209
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics (lower doses)
Study: 15309209
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (in general)
Study: 11913304
Drug: ARM &
Normalized name: Arm & Hammer Peroxicare Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARM & HAMMER Dental Care The Baking Soda Gum (AHDC) - sugar-free chewing gum, 2 pieces, twice a day for 20 minutes
Study: 11913304
Drug: breath mints
Approvals — FDA: no, EMA: no, PMDA: no
Description: breath mints (study placebo), twice a day
Study: 8260118
Drug: Continuous sulphonylurea
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sulphonylurea therapy (glibenclamide for 16 weeks)
Study: 8260118
Drug: Intermittent sulphonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sulphonylurea therapy (glibenclamide for 2 weeks then placebo for 2 weeks for 16 weeks)
Study: 3733281
Drug: Buffered preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered preparations
Study: 3733281
Drug: Plain compressed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain compressed aspirin
Study: 17598653
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg/d for 4 weeks
Study: 15858933
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day) with aspirin (100 mg/day)
Study: 15858933
Drug: Ticlopidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (200 mg/day) with aspirin (100 mg/day)
Study: 7644776
Drug: Zardaverine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zardaverine (1.5 mg, 3.0 mg, or 6.0 mg)
Study: 7644776
Drug: Salbutamol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.3 mg)
Study: 1259126
Drug: Fentanyl (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.01 mg/kg, n = 7)
Study: 1259126
Drug: Althesin (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althesin (0.075 mg/kg, n = 9)
Study: 31178967
Drug: PR antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR antioxidant group (α‐tocopherol: 30 mg/day, ascorbate: 180 mg/day, zinc gluconate: 15 mg/day, selenomethionine: 50 μg/day)
Study: 28677877
Drug: BMS-986231 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986231 (3, 5, 7 or 12 µg/kg/min)
Study: 23908084
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg flurbiprofen axetil intravenously 15 minutes before surgical incision and 6 hours later (group F)
Study: 23908084
Drug: Intravenous 5
Normalized name: immune globulin intravenous 5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5 mL intralipid as a control (group C)
Study: 21983214
Drug: MF-59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-59-adjuvanted influenza vaccine (Novartis Vaccines)
Study: 21983214
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine subunit (GSK)
Study: 11777291
Drug: Simvastatin 120
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 120 mg
Study: 10190709
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% (OFLX), 0.25 ml topically bid for 10 days
Study: 10190709
Drug: Systemic amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic amoxicillin/clavulanate (AUG), 40 mg/kg per day for 10 days
Study: 10190709
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% (OFLX)
Study: 10190709
Drug: Systemic amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic amoxicillin/clavulanate (AUG)
Study: 10190709
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% (OFLX) and Systemic amoxicillin/clavulanate (AUG)
Study: 3052183
Drug: Captopril (C)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (C) 25 mg tid
Study: 3052183
Drug: Nicardipine (N)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (N) 20 mg tid
Study: 29292054
Drug: Beclomethasone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 100 mcg plus Formoterol 6 mcg (BDP/F)
Study: 29292054
Drug: Fluticasone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 125 mcg plus Salmeterol 25 mcg (FP/S)
Study: 28895794
Drug: Synbiotics (Probinul
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (Probinul Neutro, CadiGroup, Rome, Italy), 5 g powder packets dissolved in water three times a day for 30 days
Study: 21317794
Drug: TBR-652 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 25 mg
Study: 21317794
Drug: TBR-652 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 50 mg
Study: 21317794
Drug: TBR-652 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 75 mg
Study: 21317794
Drug: TBR-652 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 150 mg
Study: 19268976
Drug: Levodopa combined
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa combined with language therapy
Study: 12775198
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy with a home program
Study: 10843028
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone 50 mg/kg
Study: 10843028
Drug: No second
Approvals — FDA: no, EMA: no, PMDA: no
Description: No second dose of ceftriaxone
Study: 2467496
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg t.d.s.
Study: 2467496
Drug: Hydroxyzine hydrochloride
Normalized name: hydroxyzine hydrochloride
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine hydrochloride 20 mg t.d.s.
Study: 23680059
Drug: Insulin (INS)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (INS)
Study: 24579987
Drug: First-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation drug-eluting stents (DES)
Study: 20092882
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (lithium plus valproate)
Study: 18447213
Drug: Tiaoshen Fuyin
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaoshen Fuyin acupuncture therapy combined with language training
Study: 1524913
Drug: ciprofloxacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin (1 g/day)
Study: 1524913
Drug: co‐trimoxazole (1920
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole (1920 mg/day) plus colistin (800 mg/day)
Study: 3516703
Drug: Pirmenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol (50 mg intravenous injection followed by 2.5 mg min‐1 infusion)
Study: 3516703
Drug: Lidocaine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (75 mg injection followed by 3 mg min‐1 infusion)
Study: 27257049
Drug: Concomitant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant Therapy (CT)
Study: 24102806
Drug: Autologous cord
Normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cord blood infusion
Study: 20884874
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (increased during fasting)
Study: 1505413
Drug: Dapsone-pyrimethamine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone-pyrimethamine (50-100 mg dapsone and 6.25-12.5 mg pyrimethamine weekly)
Study: 23213757
Drug: Epley's manoeuvre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epley's manoeuvre plus labyrinthine sedative (Betahistine mesilate, flunarizine hydrochloride, Ginkgo biloba)
Study: 8549941
Drug: Cholestyramine 4
Normalized name: CHOLESTYRAMINE 4GM CHEW BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 4 g twice daily
Study: 8549941
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin and cholestyramine
Study: 42976
Drug: Mouth and
Normalized name: Oracoat Xyligel Dry Mouth And Lip Citrus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth and throat disinfectant lozenges (sugar-containing)
Study: 42976
Drug: Sugar-free mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free mouth and throat disinfectant lozenge
Study: 31552551
Drug: Vortioxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10 mg single dose, 10 mg and 20 mg multiple daily doses)
Study: 28373452
Drug: TACE using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE using drug-eluting beads (DEBs) loaded with doxorubicin
Study: 28373452
Drug: TACE using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE using polyethylene glycol drug-elutable microspheres (PEG) loaded with doxorubicin
Study: 23900878
Drug: Macitentan (1-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan (1-30 mg)